Given that SP promotes glioma aggressiveness through NK‐1R signaling and that NK‐1R antagonism with aprepitant effectively inhibits these pathways, our results support the potential of NK‐1R antagonists as novel therapeutic agents in glioblastoma management. This evidence concerns the gene TACR1 and glioblastoma.